Tislelizumab/Chemo Approved by European Commission For ESCC/GEJ
The European Commission has approved tislelizumab plus chemotherapy as treatment for patients with esophageal and gastric or GEJ cancer.
Advancing Research and Targeting Genomic Alterations in Pancreatic Cancer
Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.
Tiragolumab/Atezolizumab Does Not Meet OS End Point in Metastatic NSCLC
Tiragolumab with atezolizumab, when compared with placebo with atezolizumab, failed to reach its overall survival end point in patients with NSCLC.
Collaboration Fosters Treatment Advancements for Young Lymphoma Populations
A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.
Capivasertib Combo Significantly Improves rPFS in PTEN-Deficient HSPC
Data show an early trend towards improved overall survival with capivasertib plus abiraterone and androgen deprivation therapy in CAPItello-281.
SPM AE Incidence After CAR T-Cell Therapy in Lymphoma and Myeloma
Findings from the Phase 3 AURIGA trial support the use of lenalidomide plus daratumumab vs lenalidomide alone as post-transplant maintenance therapy for patients with newly diagnosed multiple myeloma.
